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Abstract
PURPOSE: To study the contribution of immunologic
background to the uptake of fluorine-18-fluorodeoxy-
glucose (18F-FDG) by the tumor tissues. METHODS:
The uptakes of 18F-FDG to the same experimental
tumor model (SCCVII ) xenografted into immunocom-
petent and immunodeficient (athymic ) mice were
compared. In addition, the immunomodifying effect of
steroid on the uptake of 18F-FDG by these tumors was
investigated. RESULTS: The uptake of 18F-FDG by the
tumors in immunocompetent mice was significantly
higher than that in immunodeficient (athymic) mice.
Although steroid pretreatment had no effect on the
tumor uptake in immunodeficient mice, it significantly
decreased the tumor uptake in immunocompetent mice.
CONCLUSION: The higher tumor uptake of 18F-FDG
observed in immunocompetent mice, modulated by
steroid pretreatment, was contributed by the host
immune reaction, probably cellular immunity employed
by T-lymphocytes. These findings can clinically con-
clude that the intense accumulation of 18F-FDG in the
metastatic lymph nodes, which contain only a small
number of cancer cells, was caused by the enhanced
uptake of 18F-FDG by activated T-lymphocytes due to
host immunity against cancer cells present in metastatic
lymph nodes.
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Introduction
Fluorine-18- fluorodeoxyglucose (18F-FDG) has been
approved by the HFCA for clinical application, and is
currently extensively used in oncologic patients to detect
the enhanced glycolysis of the malignant tumor tissues using
positron emission tomography (PET) technique. The useful-
ness of 18F-FDG-PET in the management of cancer
patients has been reported in various situations, such as
differentiating benign from malignant lesions, preoperative
staging including lymph node metastasis, follow-up of
postoperative patients, evaluation of therapeutic effect, and
so on [1,2–5]. Although 18F-FDG is a valuable cancer-
seeking agent, it has also been reported to accumulate in
acute and chronic inflammatory lesions, granulomatous
diseases, and autoimmune diseases [6–8]. In those cases,
18F-FDG is expected to be taken up by inflammatory cells
such as granulocytes, lymphocytes, macrophages, and so
on. Because cancer tissues consist of tumor cells and
stromata, it is possible that infiltrating cells in the stromata
also take up 18F-FDG. In some specific situations where the
tumor was affected by intense host reaction, such as after
radiation therapy, 18F-FDG uptake by tumor tissues often
increases despite the decreased viability of tumor cells
[9,10]. The main purpose of this study is to evaluate the
contribution of nontumorous factors, such as host immune
reaction, on the tumor uptake of 18F-FDG and to study the
modifying effect of immunomodulators.
Materials and Methods
SCCVII Xenograft
SCCVII murine ovarian squamous cell carcinoma cells
were grown in MEM medium (Nissui Pharmaceuticals,
Tokyo, Japan), supplemented with 12.5% fetal calf serum
(GIBCO Laboratories, Grand Island, NY) and 0.03%
L-glutamine, in a 5% CO2 environment. A single cell
suspension of 2105 SCCVII cells was subcutaneously
injected into the left thighs of female immunocompetent
C3H/He or athymic BALB/c nu/nu mice. The SCCVII tumor-
bearing mice were used for biodistribution study 11 days
after the injection of cells.
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Production of FDG and Biodistribution Study
Fluorine-18 was produced by a 20Ne (d,a ) 18F nuclear
reaction in a cyclotron CYPRIS-325R (Sumitomo Heavy
Industries, Tokyo, Japan), and 18F-FDG was synthesized
by the nucleophilic substitution method with a 18F-FDG
synthesizing instrument F-100 (Sumitomo Heavy Indus-
tries) [11]. SCCVII tumor-bearing immunocompetent and
athymic mice received either a daily intraperitoneal
injection of 50 mg/kg methylprednisolone succinate
(Sigma-Aldrich Japan, Tokyo, Japan) from the 7th to the
10th day after tumor inoculation. The other group received
no treatment and served as a control. These mice were
fasted for 4 to 6 hours, and approximately 1.35103 MBq
(50 Ci) of 18F-FDG was injected in the tail vein of each
mouse. One hour after the injection of 18F-FDG, a group of
mice (n=5) was sacrificed by ether inhalation. Tumors,
blood, and various organs were removed and weighed,
and their radioactivity was counted. The percentages of
injected dose per gram of tissue (%ID/g) normalized to
20-g mouse were determined, from which tumor- to-blood
or organ- to-blood ratios were calculated.
All animal experiments were carried out in accordance
with the regulations regarding animal care and handling and
were approved by the animal care committee in the Kyoto
University. Statistical analyses of independent variables
were performed and a probability value (P ) of <.05 was
considered significant.
Results
Table 1 summarizes the biodistribution of 18F-FDG in
immunocompetent and athymic mice bearing SCCVII xeno-
grafts in a nonsteroid pretreatment group. The striking
differencewas the significantly higher tumor uptake observed
in immunocompetent mice compared to that in athymic mice
(9.96±0.47% vs 3.50±0.40%, P<.01). In addition, the
blood level of 18F-FDG was higher in immunocompetent
mice, along with uptakes in the spleen and lungs (P<.01).
Tumor-to -blood ratio was also higher in immunocompetent
mice (21.83±1.33 vs 11.47±2.07, P<.01), whereas liver -
to-blood and bone- to-blood ratios were higher in athymic
mice. After steroid pretreatment, the tumor uptake of
18F-FDG was substantially reduced only in immunocompe-
tent mice ( from 9.96±0.47% to 7.68±0.55%), but was still
significantly higher than that in athymicmice (7.68±0.55% vs
4.11±0.76%, P<.01) (Table 2). The blood level of 18F-FDG
and various organ uptakes were also higher in immuno-
competent mice after steroid pretreatment. However, tumor-
to-blood and organ- to-blood ratios did not show any
significant difference after steroid pretreatment except for
stomach- to-blood ratio.
The effects of steroid pretreatment on the biodistribution
of 18F-FDG and also on organ weight in immunocompetent
and athymic mice were compared and the results were
summarized in Figure 1. In immunocompetent mice, steroid
pretreatment significantly reduced the uptake of 18F-FDG in
the liver and SCCVII tumors (P<.01), and also significantly
reduced the tumor- to-blood ratio (P<.01). In contrast, in
athymic mice, steroid pretreatment did not affect the tumor
uptake of 18F-FDG. Tumor- to-blood ratio rather increased a
little. The weight of the spleen significantly decreased after
steroid administration in both immunocompetent and athy-
mic mice (Figure 1c ), whereas there was no difference in
tumor weight in both mice.
Discussion
In the present study, the biodistribution of 18F-FDG in
immunocompetent and athymic mice bearing the same
SCCVII xenograft was compared along with the effect of
steroid pretreatment. The uptake of 18F-FDG in SCCVII
tumor was significantly higher in immunocompetent than
in athymic mice. Both mice were transplanted with the
same cancer cells, which similarly formed tumor in both
mice, with no apparent difference in histology. Therefore,
differences in the metabolic activity of cancer cells are
not likely a cause of the difference in 18F-FDG uptakes.
Table 1. Biodistribution of 18F -FDG in Immunocompetent and Athymic Mice
Bearing SCCVII Xenografts Without Steroid Pretreatment.
Organ %ID /g Organ - to - blood ratio
Immunocompetent Athymic Immunocompetent Athymic
Blood 0.46±0.04* 0.31±0.03 – –
Liver 0.89±0.04 0.79±0.12 1.96±0.27y 2.57±0.30
Kidney 1.33±0.16 1.08±0.23 2.90±0.31 3.53±0.90
Intestine 2.63±0.43 2.08±0.18 5.75±0.74 6.79±0.83
Stomach 1.57±0.27 1.17±0.21 3.43±0.45 3.87±0.94
Spleen 2.39±0.30* 1.58±0.13 5.25±0.76 5.16±0.63
Lung 2.18±0.18* 1.66±0.12 4.79±0.59 5.45±0.79
Muscle 2.61±1.17 1.43±0.34 5.72±2.44 4.72±1.37
Bone 1.29±0.25 1.61±0.14 2.84±0.56 5.24±0.68
SCCVII 9.96±0.47* 3.50±0.40 21.83±1.33* 11.47±2.07
%ID /g represents percentages of injected dose per gram of tissue after
1 hour of intravenous injection of 18F -FDG. Values are expressed in
mean±SD of five mice.
*Represents P< .01 between immunocompetent and athymic mice.
yRepresents P< .05 between immunocompetent and athymic mice.
Table 2. Biodistribution of 18F -FDG in Immunocompetent and Athymic Mice
Bearing SCCVII Xenografts With Steroid Pretreatment.
Organ %ID /g Organ - to -blood ratio
Immunocompetent Athymic Immunocompetent Athymic
Blood 0.44±0.05* 0.27±0.04 – –
Liver 0.68±0.07* 0.47±0.07 1.55±0.20 1.74±0.05
Kidney 1.70±0.21* 1.14±0.14 3.95±0.89 4.22±0.70
Intestine 3.00±0.89y 1.69±0.17 6.75±1.55 6.22±0.35
Stomach 1.06±0.16 1.31±0.14 2.47±0.67* 4.89±0.96
Spleen 2.43±0.24y 1.78±0.31 5.59±0.86 6.55±0.92
Lung 1.87±0.16 1.65±0.53 4.32±0.65 6.05±1.72
Muscle 2.28±0.48y 1.36±0.42 5.23±1.05 5.23±2.23
Bone 1.23±0.22 1.10±0.40 2.86±0.77 4.19±1.96
SCCVII 7.68±0.55* 4.11±0.76 17.56±1.03 15.11±1.83
%ID /g represents percentages of injected dose per gram of tissue after
1 hour of intravenous injection of 18F -FDG. Values are expressed in
mean±SD of five mice.
*Represents P< .01 between immunocompetent and athymic mice.
yRepresents P< .05 between immunocompetent and athymic mice.
180 Effects of Steriod Pretreatment on Tumor Uptake of 18F-FDG Mamede et al.
Neoplasia . Vol. 5, No. 2, 2003
The difference in immunologic backgrounds ( i.e., the
presence or absence of host immune reaction) is the
major factor in the different 18F-FDG uptakes in the same
SCCVII tumors.
Due to the tumorigenicity of SCCVII cells and the
availability of athymic mouse, we could not use the
identical strain of immunocompetent and athymic mice.
However, normal mice of different strains showed similar
pharmacokinetics of 18F-FDG (data not shown). How-
ever, it is possible that the pharmacokinetics of 18F-FDG
in immunocompetent mice is not completely identical to
that in athymic mice. Actually, 18F-FDG tended to be
cleared more slowly from the blood and some normal
organs in immunocompetent (C3H/He) mice than in
athymic (BALB/c nu/nu) mice. Therefore, a higher tumor
uptake of 18F-FDG in immunocompetent mice may be
contributed, in part, by this slower clearance of 18F-FDG
from the body. However, in addition to percent uptake in
the tumor, tumor- to-blood ratio was also significantly
higher in immunocompetent mice and the difference in
the immunologic background seemed to be the major
contributor.
Figure 1. The effect of steroid pretreatment in immunocompetent (C3H /He ) and athymic (Balb / c nu / nu ) mice bearing xenografted tumors. ( a ) The effect on
percentage of injected dose per gram (%ID /g ); ( b ) the effect on organ - to - blood ratio; and ( c ) the effect on organ weight. (& ) nu / nu without steroid pretreatment
(nu /nu— control ); (5 ) nu / nu with steroid pretreatment (nu /nu— steroid ); ( ) C3H without steroid pretreatment (C3H— control ); and ( ) C3H with steroid
pretreatment (C3H— steroid ). Mean±SD of five mice: *P< .01 and **P< .05 between immunocompetent and athymic mice.
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The previous literatures reported two opposite observa-
tions. Kubota et al. [12,13] beautifully demonstrated that a
high accumulation of 18F-FDG was shown in macrophages
and granulation tissues in experimental syngeneic tumor
xenografted in immunocompetent C3H/He mice, which is
similar to our model used in the current study. In contrast,
Brown et al. [14 ] reported that 3H-FDG mostly accumulated
in viable cells of rat syngeneic breast cancer rather than in
macrophages and granulation tissues. We suggested that
differences between two observations might be caused by a
variability of the host immune response against implanted
tumor cells. We were not able to obtain a successful
microautoradiography to identify the responsible cells taking
up 18F-FDG using the same method as we used in our
previous study [15] because of poor resolution. However, we
found numbers of small necrotic foci and mild but diffuse
infiltrations of mononuclear cells on hematoxylin and eosin
sections of SCCVII tumors growing in both immunocompe-
tent and athymic mice. Therefore, SCCVII tumors would be
clearly recognized by the host immune system in both mice.
In vivo tumor growth can be allowed, only when host
immunity missed the tumor tissue to some extent. Therefore,
in case the host immune system did not recognize or fully
respond against tumor cells, host cells would not greatly
contribute to 18F-FDG accumulation in tumor tissue as we
found in athymic mice.
Steroids are reported to have powerful anti - inflammatory
effects and to induce the apoptosis of lymphocytes
[15–21]. Some authors have reported the shrinkage of
spleen following the use of steroids due to a large-scale
destruction of lymphocytes (B and T), which was also
observed in the present study. The present investigation
showed that steroid pretreatment significantly reduced the
tumor uptake of 18F-FDG only in immunocompetent mice.
Because steroid had no effect on the tumor uptake in athymic
mice, it is unlikely that this dose of steroid directly affected
the metabolic activity of cancer cells. The effect of steroid on
activated lymphocytes (especially T-cells ) infiltrating in the
cancer stroma, therefore, is a possible mechanism of action.
In immunocompetent mice, xenografted tumor is recognized
by the host immune system, and there should be activated
immune cells in the cancer stromata.
Steroids are reported to induce the elevation of plasma
glucose level that might change the tumor uptake of
18F-FDG [22]. However, we did not detect any significant
hyperglycemia in other sets of mice, which were injected with
the same dose of steroids as we used in this study (data not
shown). Because this elevated amount of plasma glucose
was much smaller than reported values, which can alter the
tissue uptake of 18F-FDG [22,23], the effect of hyper-
glycemia to the tumor uptake of 18F-FDG would not be
substantial in this model.
In addition, in our recent work using concanavalin A, a
potent stimulator of T- lymphocytes, we have reported that
concanavalin A increased the 18F-FDG uptake both in vitro
and in vivo by splenic cells and infiltrating mononuclear cells
in the liver, resulting in alteration of the biodistribution of
18F-FDG in immunocompetent mice [15].
In clinical situations, we sometimes observed that the
18F-FDG accumulation in metastatic lymph nodes was
extremely high in spite of smaller number of cancer cells
contained in the lymph node. The findings in the present
study could explain the intense uptake of 18F-FDG by the
metastatic lymph nodes because lymph nodes contain a
large number of lymphocytes, which can be activated by
the presence of cancer cells. These activated immune
cells take up 18F-FDG and make the lymph node uptake
of 18F-FDG very high, and can increase the detectability
of metastatic lymph nodes with the clinical 18F-FDG-PET
scan.
In conclusion, the present study showed that a sub-
stantial amount of 18F-FDG uptake by the tumor tissues
was contributed by the immunologic response in an
immunocompetent host, which could be modulated by
immunomodulators.
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